CT LUCIA Intraocular Lenses (IOLs)
Carl Zeiss Meditec Production, LLC · Decision date Oct 23, 2026
What did the FDA decide?
FDA database record P100016/S028, dated 2026-10-23, is a 30-Day Notice for CT LUCIA intraocular lenses from Carl Zeiss Meditec Production, LLC. The decision field reads OK30. The statement describes changes to the tray raw material and lid coating for the CT LUCIA 621P IOL, plus a sterilization process change removing the ambient aeration step from the ethylene oxide sterilization process for CT LUCIA 202, CT LUCIA 602, and CT LUCIA 621P IOLs.
The supplement type is a 30-Day Notice and the supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier. This is not a new approval of the original PMA system. The record does not state whether the changes affect safety or clinical effectiveness. No clinical outcome data, trial information, or indication changes appear in the supplied fields.
FDA approval order statement
changes to the tray raw material and lid coating for CT LUCIA 621P Intraocular lens (IOL) and a sterilization process change involving the removal of the ambient aeration step from the Ethylene Oxide (EO) sterilization process for CT LUCIA 202, CT LUCIA 602, and CT LUCIA 621P IOLs
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100016/S028
- Regulatory pathway
- PMA supplement
- Applicant
- Carl Zeiss Meditec Production, LLC
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Carl Zeiss Meditec Production, LLC
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100016 · Original PMA
EC-3 INTRAOCULAR LENS (IOL) AND EC-3 PRECISION ASPHERIC LENS (PAL) IOL
P100016/S028 received
Application receipt date recorded by FDA.
P100016/S028 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P100016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Carl Zeiss Meditec Production, LLC | PMA approval | Oct 19, 2010 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Carl Zeiss Meditec Production, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1040 S. Vintage Ave., Bldg. A, Ontario, CA, 91761
Sources and methodology
- Original FDA record: P100016/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



